中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
27期
95-96,103
,共3页
甲磺酸伊马替尼%常规方法%慢性粒细胞白血病%治疗效果
甲磺痠伊馬替尼%常規方法%慢性粒細胞白血病%治療效果
갑광산이마체니%상규방법%만성립세포백혈병%치료효과
Imatinib mesylate%Conventional method%Chronic myelocytic leukemia%Treatment effect
目的 探讨甲磺酸伊马替尼和常规方法在慢性粒细胞白血病患者中的临床治疗效果. 方法 随机选取2013年2月-2015年2月收治的80例慢性粒细胞白血病患者资料进行分析,根据不同治疗方案将患者分为两组,实验组采用甲磺酸伊马替尼治疗,对照组采用常规化疗治疗,比较两组疗效. 结果 实验组35例完全缓解,3例部分缓解,缓解率为95%,显著高于对照组(27例完全缓解、7例部分缓解,缓解率为85%)(P<0.05);两组治疗前CD3+、CD4+、CD4+/CD8+等T淋巴细胞指标差异无统计学意义(P>0.05);实验组治疗后CD3+、CD4+、CD4+/CD8+等T淋巴细胞指标显著高于对照组(P<0.05). 结论 慢性粒细胞白血病患者采用甲磺酸伊马替尼治疗效果理想,能够改善患者症状及其免疫功能,值得推广使用.
目的 探討甲磺痠伊馬替尼和常規方法在慢性粒細胞白血病患者中的臨床治療效果. 方法 隨機選取2013年2月-2015年2月收治的80例慢性粒細胞白血病患者資料進行分析,根據不同治療方案將患者分為兩組,實驗組採用甲磺痠伊馬替尼治療,對照組採用常規化療治療,比較兩組療效. 結果 實驗組35例完全緩解,3例部分緩解,緩解率為95%,顯著高于對照組(27例完全緩解、7例部分緩解,緩解率為85%)(P<0.05);兩組治療前CD3+、CD4+、CD4+/CD8+等T淋巴細胞指標差異無統計學意義(P>0.05);實驗組治療後CD3+、CD4+、CD4+/CD8+等T淋巴細胞指標顯著高于對照組(P<0.05). 結論 慢性粒細胞白血病患者採用甲磺痠伊馬替尼治療效果理想,能夠改善患者癥狀及其免疫功能,值得推廣使用.
목적 탐토갑광산이마체니화상규방법재만성립세포백혈병환자중적림상치료효과. 방법 수궤선취2013년2월-2015년2월수치적80례만성립세포백혈병환자자료진행분석,근거불동치료방안장환자분위량조,실험조채용갑광산이마체니치료,대조조채용상규화료치료,비교량조료효. 결과 실험조35례완전완해,3례부분완해,완해솔위95%,현저고우대조조(27례완전완해、7례부분완해,완해솔위85%)(P<0.05);량조치료전CD3+、CD4+、CD4+/CD8+등T림파세포지표차이무통계학의의(P>0.05);실험조치료후CD3+、CD4+、CD4+/CD8+등T림파세포지표현저고우대조조(P<0.05). 결론 만성립세포백혈병환자채용갑광산이마체니치료효과이상,능구개선환자증상급기면역공능,치득추엄사용.
Objective To investigate imatinib mesylate and conventional methods in the clinical treatment of patients with chronic myelocytic leukemia. Methods 80 patients with chronic myelocytic leukemia data from February 2013 to February 2015 were ana-lyzed according to the different treatment patients were divided into two groups, the experimental group mesylate Iraq imatinib treatment, the two groups were compared, the control group with conventional chemotherapy treatment. Results 35 cases of com-plete remission, three cases of partial remission, remission rate of 95%, which was significantly higher (27 cases of complete remis-sion, seven cases of partial remission, response rate 85%) (P<0.05);two before treatment, CD3+, CD4+, CD4 +/CD8 + and other T lymphocytes index was not significantly different (P>0.05);the experimental group after treatment CD3+, CD4+, CD4+/CD8+and other T lymphocytes index was significantly higher (P<0.05). Conclusion Patients with chronic myelocytic leukemia using imatinib mesylate desired effect, can improve symptoms and immune function, should be introduced.
